These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 3311840)

  • 21. [Study of the intracytoplasmatic antigens of malignant melanoma cells. Preliminary report].
    De Moragas J; Anguera A; Viñas J
    Actas Dermosifiliogr; 1971; 62(9):429-32. PubMed ID: 4949557
    [No Abstract]   [Full Text] [Related]  

  • 22. [Clinical application of monoclonal antibodies to human malignant melanoma-associated antigens].
    Kageshita T; Ishihara K
    Gan To Kagaku Ryoho; 1985 Sep; 12(9):1744-8. PubMed ID: 3899015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of serum anti-melanocyte antibodies and identification of related antigens in patients with vitiligo.
    Zhu MC; Liu CG; Wang DX; Zhan Z
    Genet Mol Res; 2015 Dec; 14(4):16060-73. PubMed ID: 26662399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Qualitative difference between the cytotoxic T lymphocyte responses to melanocyte antigens in melanoma and vitiligo.
    Palermo B; Garbelli S; Mantovani S; Scoccia E; Da Prada GA; Bernabei P; Avanzini MA; Brazzelli V; Borroni G; Giachino C
    Eur J Immunol; 2005 Nov; 35(11):3153-62. PubMed ID: 16224813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidermal cytoplasmic antibodies. (Incidence and clinical significance).
    Betterle C; Peserico A; Bersani G; Rigon F; Del Prete G
    Ric Clin Lab; 1977; 7(3):242-51. PubMed ID: 343221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo.
    Uchi H; Stan R; Turk MJ; Engelhorn ME; Rizzuto GA; Goldberg SM; Wolchok JD; Houghton AN
    Adv Immunol; 2006; 90():215-41. PubMed ID: 16730265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of tumor-regression antigens in melanoma.
    Kawakami Y; Robbins PF; Wang RF; Rosenberg SA
    Important Adv Oncol; 1996; ():3-21. PubMed ID: 8791125
    [No Abstract]   [Full Text] [Related]  

  • 28. [Autoantibodies in vitiligo. Clinical significance].
    Morgan M; Castells A; Ramírez A
    Med Cutan Ibero Lat Am; 1986; 14(2):139-42. PubMed ID: 3528710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?
    Garbelli S; Mantovani S; Palermo B; Giachino C
    Pigment Cell Res; 2005 Aug; 18(4):234-42. PubMed ID: 16029417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunology of malignant melanoma].
    Bourgoin JJ
    Ann Inst Pasteur (Paris); 1972 Apr; 122(4):789-807. PubMed ID: 4559237
    [No Abstract]   [Full Text] [Related]  

  • 31. [Melanocyte antibodies in idiopathic vitiligo (author's transl)].
    Höfs T; Zugehör M; Morenz J
    Dermatol Monatsschr; 1981 Nov; 167(11):685-92. PubMed ID: 7044847
    [No Abstract]   [Full Text] [Related]  

  • 32. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
    Rosenberg SA; White DE
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of antibodies to human melanoma cell in vitiligo by western blot analysis.
    Hann SK; Kim JB
    Yonsei Med J; 1995 Nov; 36(5):457-61. PubMed ID: 8546004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein.
    Hara I; Takechi Y; Houghton AN
    J Exp Med; 1995 Nov; 182(5):1609-14. PubMed ID: 7595233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibodies to normal human melanocytes in vitiligo.
    Naughton GK; Eisinger M; Bystryn JC
    J Exp Med; 1983 Jul; 158(1):246-51. PubMed ID: 6345714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Smyth chicken melanocyte autoantibodies: cross-species recognition, in vivo binding, and plasma membrane reactivity of the antiserum.
    Searle EA; Austin LM; Boissy YL; Zhao H; Nordlund JJ; Boissy RE
    Pigment Cell Res; 1993 Jun; 6(3):145-57. PubMed ID: 8234200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of circulating antibody in the control of metastases.
    Lewis MG
    J Clin Pathol Suppl (R Coll Pathol); 1974; 7():83-93. PubMed ID: 4598354
    [No Abstract]   [Full Text] [Related]  

  • 38. Vitiligo and antibodies to melanocytes.
    Bystryn JC; Pfeffer S
    Prog Clin Biol Res; 1988; 256():195-206. PubMed ID: 3285350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality?
    Ram M; Shoenfeld Y
    Ann N Y Acad Sci; 2007 Sep; 1110():410-25. PubMed ID: 17911456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Immunology of malignant melanoma].
    Misgeld V
    Hautarzt; 1973 Dec; 24(12):511-9. PubMed ID: 4599321
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.